The Online Investor
Opiant Pharmaceuticals Inc (OPNT)

Opiant Pharmaceuticals is a pharmaceutical company developing medicines for addictions and drug overdose. Co. has developed NARCAN® (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses. Co.'s pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder, Opioid Use Disorder, and Acute Cannabinoid Overdose. Co.'s principal products include OPNT003 - Intranasal Nalmefene for OOR; OPNT001 - Intranasal Naloxone for Eating Disorders; OPNT002 - Nasal Naltrexone for Alcohol Use Disorder; and OPNT004 - Drinabant Injection for Acute Cannabinoid Overdose.
Company Name: 
Opiant Pharmaceuticals Inc
Drugs & Pharmaceuticals
Number of ETFs Holding OPNT: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
87th percentile
(ranked higher than approx. 87% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Opiant Pharmaceuticals Inc (OPNT) Page | The Online Investor Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.